Lipid-lowering therapy for secondary prevention in patients undergoing elective percutaneous coronary intervention (PCI)

Study identifier:NIS-CSI-DUM-2010/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

LIPID-LOWERING THERAPY FOR SECONDARY PREVENTION IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION (PCI) A 10-week, open-label, non-interventional study of total cholesterol/LDL-cholesterol management in real life in coronary patients hospitalised for elective PCI

Medical condition

Coronary artery disease

Phase

-

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

120

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Sept 2010
Primary Completion Date: 01 Mar 2011
Study Completion Date: 01 Mar 2011

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria